Epstein Secrets

Takeaways from FOURIER "We've never been able to plumb these depths before." lead author Marc S. Sabatine, MD, of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. "These data strongly suggest that patients benefit from lowering LDL cholesterol well below current targets."

uction with Evolocumab Reply-To: Cardiology Alert <I Email not displaying correctyNiaw it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study. presented at the 2

L to lowest, 74 mg/dL). 'We've never been able to plumb these depths before," lead author Marc S. Sabatine, MD, of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. "These data strongly suggest that patients benefit from lowering LDL cholesterol well below current targets."

cumab Reply-To: Cardiology Alert < EFTA00447987 Entail not displaying coirectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2

owest, 74 mg/dL). IIr 'We've never been able to plumb these depths before," lead author Marc S. Sabatine, MD. of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. -These data strongly suggest that patients benefit from lowering LDL cholesterol well below current targets."

eduction with Evolocumab Reply-To: Cardiology Alert E— ail not displaying conectly?View it in your browser. FOURIER: Significant LDL Reduction with Evolocumab New data from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study, presented at the 2